Targeted immunotherapy for non-small cell lung cancer

doi:10.5306/wjco.v5.i2.39

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 2

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5905)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

264

WORD

211

HTML

2867

Figures (1-1)

222

Tables (1-2)

545

Sum=4109

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

832

Download

964

Sum=1796

May 10, 2014 (publication date) through Jan 11, 2025

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Clin Oncol. May 10, 2014; 5(2): 39-47
Published online May 10, 2014. doi: 10.5306/wjco.v5.i2.39

Table 2 Ongoing clinical trials of programmed death ligand 1 mAbs in non-small cell lung cancer

Therapy	Trial	Study population	Study design	Ref.
MPDL3280A	NCT01846416	Advanced NSCLC, tumor positive for PD-L1 on IHC	Assess safety, efficacy and objective response rates in patients with PD-L1 positive NSCLC	[64]
MPDL3280A	NCT01903993	Advanced NSCLC, failed platinum based chemo	MPDL-3280A vs Docetaxel after failure of platinum based therapy in patients with advanced NSCLC	[65]

NSCLC: Non-small cell lung cancer; PD-L1: Programmed death ligand 1; IHC: Immunohistochemistry.

Citation: Vasekar M, Liu X, Zheng H, Belani CP. Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol 2014; 5(2): 39-47
URL: https://www.wjgnet.com/2218-4333/full/v5/i2/39.htm
DOI: https://dx.doi.org/10.5306/wjco.v5.i2.39